New Clinical Trial Information: GA101 Monotherapy

Trial Information: 180 patients with relapsed indolent lymphoma, including follicular lymphoma, will be recruited to test GA101 (aka RO5072759) monotherapy. Although this is a Phase II trial, patients will be randomized to receive either GA101 monotherapy or rituximab monotherapy.

Clinical Trial Information: GA-101 and Bendamustine

Trial Information: This is a Phase III trial recruiting 360 Canadian and American patients with indolent lymphoma, including follicular lymphoma, who have been previously treated and are refractory to rituximab. Patients will be randomized to receive bendamustine monotherapy or bendamustine with GA-101 (B-G).